July 17, 2024- Pfizer Inc. announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career. This process is expected to last several months, probably through early next year. Pfizer will initiate an external search for a new Chief Scientific Officer, and Dr. Dolsten will assist in this search and continue to serve in his current position until his successor is in place and any necessary transition is complete.
During his tenure at Pfizer, the company has received so far, more than 35 drug and vaccines approvals of which more than half were new molecular entities. These include products ranging from therapies for inflammatory diseases, cardiovascular, stroke prevention, hemophilia and cancer, to Pfizer’s vaccines for RSV, pneumococcal and meningococcal diseases, with his most significant accomplishments being the development and subsequent approval of the company’s COVID-19 vaccine and oral therapeutic.